Research & Literature

Amantadine-Induced Livedo Racemosa.

Criado PR, Alavi A, Valente NY, Sotto MN

The international journal of lower extremity wounds 2016; (15(1)):78-81 doi:10.1177/1534734615603566.

Successful Treatment of Livedoid Vasculitis with Primary Antiphospholipid Syndrome by Using Aspirin and Low Dose Warfarin Combination Therapy.

So BJ, Park JB, Yoo MG, et al.

Annals of dermatology 2015; (27(5)):614-5 doi:10.5021/ad.2015.27.5.614.

Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.

Weishaupt C, Strölin A, Kahle B, et al.

The Lancet. Haematology 2016; (3(2)):e72-9.

Successful treatment of livedoid vasculopathy with rivaroxaban.

Evans JM, Jensen JD, Sami N

JAAD case reports 2015; (1(6)):340-1 doi:10.1016/j.jdcr.2015.08.002.

Analysis of the German DRG data for livedoid vasculopathy and calciphylaxis.

Renner R, Dissemond J, Goerge T, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(11)):1884-1889 doi:10.1111/jdv.14190.

Dermoscopic features of livedoid vasculopathy.

Hu SC, Chen GS, Lin CL, et al.

Medicine 2017; (96(11)):e6284 doi:10.1097/MD.0000000000006284.

Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban.

Drerup C, Goerge T

Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(12)):e532 doi:10.1111/jdv.14404.

Three cases of lymphocytic thrombophilic arteritis presenting with an annular eruption.

Kelly RI, Wee E, Tancharoen C, et al.

The Australasian journal of dermatology 2018; (59(2)):e127-e132 doi:10.1111/ajd.12679.

Treatment for Livedoid Vasculopathy: A Systematic Review.

Micieli R, Alavi A

JAMA dermatology 2018; (154(2)):193-202 doi:10.1001/jamadermatol.2017.4374.

Livedoid Vasculopathy Presenting in a Patient With Sickle Cell Disease.

Reagin H, Marks E, Weis S, Susa J

The American Journal of dermatopathology 2018; (40(9)):682-685 doi:10.1097/DAD.0000000000001133.

Dermoscopy of early non-ulcerated livedoid vasculopathy.

Wollina U

Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2018; (27(3)):147-148.

Systemic lupus erythematosus with refractory ulcerated livedoid vasculopathy: Successful treatment with intravenous immunoglobulin and warfarin.

Yoshioka K, Tateishi C, Kato H, Chen KR

Clinical case reports 2018; (6(11)):2045-2047 doi:10.1002/ccr3.1803.

Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.

Weishaupt C, Strölin A, Kahle B, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(9)):1784-1791 doi:10.1111/jdv.15639.

Retiform non-blanchable purpuric plaques in a patient with systemic lupus erythematosus.

Grinnell M, Bath A, DiMaio D, et al.

Lupus 2019; (28(8)):1013-1016 doi:10.1177/0961203319847274.

Livedoid vasculopathy: does hyperhomocysteinaemia play an aetiological role?

Marsch WC, Komatsuzaki S, Mueller A, et al.

European journal of dermatology : EJD 2019; (29(3)):287-293 doi:10.1684/ejd.2019.3554.

Livedoid vasculopathy: how to diagnose and how to treat?

Lipsker D

Journal of the European Academy of Dermatology and Venereology : JEADV 2019; (33(9)):1627-1628 doi:10.1111/jdv.15830.

Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.

Gao Y, Jin H

The Journal of dermatological treatment 2022; (33(1)):178-183 doi:10.1080/09546634.2020.1737634.

Direct immunofluorescence findings in livedoid vasculopathy: a 10-year study and literature review.

Nuttawong S, Chularojanamontri L, Trakanwittayarak S, et al.

Clinical and experimental dermatology 2021; (46(3)):525-531 doi:10.1111/ced.14464.

Livedoid vasculopathy in 75 Brazilian patients in a single-center institution: Clinical, histopathological and therapy evaluation.

Criado PR, Pagliari C, Morita TCAB, et al.

Dermatologic therapy 2021; (34(2)):e14810 doi:10.1111/dth.14810.

Livedoid vasculopathy and its association with genetic variants: A systematic review.

Gao Y, Jin H

International wound journal 2021; (18(5)):616-625 doi:10.1111/iwj.13563.

Rivaroxaban for treatment of livedoid vasculopathy: A systematic review.

Gao Y, Jin H

Dermatologic therapy 2021; (34(5)):e15051 doi:10.1111/dth.15051.

Adalimumab in Treating Refractory Livedoid Vasculopathy.

Huang XW, Zheng HX, Wang ML, et al.

Vaccines 2022; (10(4)) doi:10.3390/vaccines10040549.

Livedo racemosa in lymphocytic vasculitis.

Toh C, Choi ECE, Tan CL

QJM : monthly journal of the Association of Physicians 2022; (115(12)):866-867 doi:10.1093/qjmed/hcac198.

Livedoid vasculopathy - A diagnostic and therapeutic challenge.

Burg MR, Mitschang C, Goerge T, Schneider SW

Frontiers in medicine 2022; (9()):1012178 doi:10.3389/fmed.2022.1012178.

Refractory livedoid vasculopathy successfully treated with baricitinib.

Xiao Y, Wang Y, Gu Y, et al.

International journal of dermatology 2023; (62(9)):1204-1205 doi:10.1111/ijd.16467.

Clinical, Laboratory, Histopathological and Therapeutic Profile of Livedoid Vasculopathy: A Case Series of 17 Patients.

Shah SR, Vyas HR, Doshi YJ, Shah BJ

Indian dermatology online journal 2022; (13(6)):771-774 doi:10.4103/idoj.idoj_182_22.

Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy.

Han Y, Tu P

Frontiers in immunology 2022; (13()):1008392 doi:10.3389/fimmu.2022.1008392.

A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy.

Seguí M, Llamas-Velasco M

Frontiers in medicine 2022; (9()):993515 doi:10.3389/fmed.2022.993515.

Pain Management Options in a Patient with Livedoid Vasculopathy and Peripheral Neuropathy.

Palanisamy N, Chinnappan J, Bachuwa G

European journal of case reports in internal medicine 2023; (10(1)):003727 doi:10.12890/2023_003727.

Penile Livedoid Vasculopathy: First Reported Case.

Hallak A, Bennett W, Tanbir MA, et al.

Case reports in vascular medicine 2023; (2023()):6920383 doi:10.1155/2023/6920383.

Punch grafting for the treatment of ulcerated atrophie blanche.

Orbea Sopeña A, Conde Montero E

Phlebology 2023; (38(10)):695-697 doi:10.1177/02683555231198993.

Lymphocytic vasculitis in livedoid vasculopathy: A report of 137 cases.

Yuan Y, Liu Y, Ban F, et al.

Journal of cutaneous pathology 2024; (51(2)):155-162 doi:10.1111/cup.14546.

Clinical characteristics of Martorell hypertensive ischaemic leg ulcer.

Karppinen JJ, Kallio M, Lappalainen K, et al.

Journal of wound care 2023; (32(12)):797-804 doi:10.12968/jowc.2023.32.12.797.

Associations between coagulation factors and livedoid vasculopathy and the efficacy and safety of rivaroxaban in patients with livedoid vasculopathy: a retrospective study.

Zhao C, Yu M, Cheng X, et al.

Clinical and experimental dermatology 2024; (49(8)):817-824 doi:10.1093/ced/llae023.

Occlusive cutaneous vasculopathies as cause of chronic ulcers.

Ronicke M, Berking C, Erfurt-Berge C

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2024; (22(4)):553-567 doi:10.1111/ddg.15276.

Inflammatory and vaso-occlusive ulcers: Part I - Clinical presentation and diagnosis.

Shakshouk H, Hines A, Kody S, et al.

Journal of the American Academy of Dermatology 2024; (91(6)):1035-1048 doi:10.1016/j.jaad.2024.01.083.

Livedoid vasculopathy.

Leeolou MC, Rieger KE, Yeh JE

Dermatology online journal 2023; (29(5)) doi:10.5070/D329562414.

Sneddon Syndrome: A Case Report From Saudi Arabia.

Madani A, Almutairi HM, Alshathry YH, et al.

Cureus 2024; (16(3)):e55509 doi:10.7759/cureus.55509.

Chronic ulcer in a patient with essential thrombocythemia taking hydroxyurea.

Maloney N, Novoa R, Yeh JE

Dermatology online journal 2024; (30(3)) doi:10.5070/D330363872.

Identification of Challenging Diagnostic Factors in Livedoid Vasculopathy: A Retrospective Study.

Qi F, Gao Y, Jin H

Clinical, cosmetic and investigational dermatology 2024; (17()):1747-1756 doi:10.2147/CCID.S466449.

Clinical and patient reported treatment outcomes of livedoid vasculopathy: a systematic review.

Gipple MO, Throckmorton SK, Gabo VB, et al.

Clinical and experimental dermatology 2025; (50(4)):856-858 doi:10.1093/ced/llae377.

Addressing Diagnostic Challenges in Livedoid Vasculopathy: A Case Report on Interdisciplinary Management.

Ríos Padín J, Rivera Rodríguez DM, Nuñez Morales J, Álvarez Cardín N

Cureus 2024; (16(10)):e72554 doi:10.7759/cureus.72554.

Livedoid vasculopathy, calciphylaxis, and Martorell's hypertensive ulcer: update on ischemic ulcers due to impaired microcirculation of the lower limbs.

Lacerda PN, Garcia LC, Mazeto IFDS, et al.

Anais brasileiros de dermatologia 2025; (100(2)):215-227 doi:10.1016/j.abd.2024.09.004.

Baricitinib Successfully Treated a Teenager with Refractory Livedoid Vasculopathy: A Case Report and Literature Review.

Liu C, Jin YY, Han X, et al.

Journal of inflammation research 2025; (18()):1471-1477 doi:10.2147/JIR.S495481.

A case report and literature review of livedoid vasculopathy in children.

Qu J, Hao Z, Junli W, Yu S

Frontiers in pediatrics 2025; (13()):1537133 doi:10.3389/fped.2025.1537133.

Autoimmune-Associated Livedoid Vasculopathy: Response to Immunomodulatory Therapy.

Aung T, Cheah JX

Cureus 2025; (17(9)):e92748 doi:10.7759/cureus.92748.

Prevalence of Livedoid Vasculopathy Among Patients with Connective Tissue Diseases and Its Association with Thrombophilic Factors: A Hospital-Based Retrospective Cohort (2014-2021).

Argobi Y

Clinical, cosmetic and investigational dermatology 2025; (18()):2971-2977 doi:10.2147/CCID.S551007.

Long-Term Efficacy of Guideline-Followed Treatment in Patients with Livedoid Vasculopathy: A Single-Center Study.

Hillgruber C, Mitschang C, Eveslage M, et al.

Advances in wound care 2025; doi:10.1177/21621918251395013.

Treatment of Livedoid Vasculopathy with the Janus Kinase Inhibitors: A Case Series.

Zhao G, Liu Y, Ni J, Song Z

Case reports in dermatology 2026; (18(1)):36-44 doi:10.1159/000549494.

Differential response to Janus kinase inhibitors in refractory livedoid vasculopathy: Biomarker-guided therapy may improve clinical response.

Yu G, Zhu J, Zhang Y, et al.

JAAD international 2026; (24()):318-319 doi:10.1016/j.jdin.2025.11.024.

Treatment outcomes in patients of livedoid vasculopathy following antithrombotic therapy: A retrospective observational study.

Gupta P, Thakur V, Behera B, et al.

Indian journal of dermatology, venereology and leprology 2026; 1-9.